$113.38
-0.42-0.37%
At close: -
$113.80
0.420.37%
After Hours: Dec 23, 4:00 PM EDT
Ligand Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Ligand Pharmaceuticals using advanced sorting and filters.
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Sep 2024 | 2024-11-07 | $1.84 | $1.35 | 36.3 % |
Jun 2024 | 2024-08-06 | $1.40 | $0.98 | 42.9 % |
Mar 2024 | 2024-05-07 | $3.84 | $0.78 | 392.3 % |
Dec 2023 | 2024-02-27 | $1.38 | $0.66 | 109.1 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Sep 2024 | 2024-11-07 | $51.81M | $40.65M | 27.5 % |
Jun 2024 | 2024-08-06 | $41.53M | $31.90M | 30.2 % |
Mar 2024 | 2024-05-07 | $30.98M | $27.92M | 10.9 % |
Dec 2023 | 2024-02-27 | $28.10M | $25.72M | 9.26 % |
Ligand Pharmaceuticals (LGND) is scheduled to report earnings on February 25, 2025. The last reported earnings were for reported on November 7, 2024 for Q3.
The Actual EPS was $1.84, which beat the estimate of $1.35.
The Actual Revenue was $51.8M, which beat the estimate of $40.6M.
Browse earnings estimates, EPS, and revenue on all stocks.